Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade
Open Access
- 22 March 2023
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-18
Abstract
Whereas the contribution of tumor microenvironment to the profound immune suppression of glioblastoma (GBM) is clear, tumor-cell intrinsic mechanisms that regulate resistance to CD8 T cell mediated killing are less understood. Kinases are potentially druggable targets that drive tumor progression and might influence immune response. Here, we perform an in vivo CRISPR screen to identify glioma intrinsic kinases that contribute to evasion of tumor cells from CD8 T cell recognition. The screen reveals checkpoint kinase 2 (Chek2) to be the most important kinase contributing to escape from CD8 T-cell recognition. Genetic depletion or pharmacological inhibition of Chek2 with blood-brain-barrier permeable drugs that are currently being evaluated in clinical trials, in combination with PD-1 or PD-L1 blockade, lead to survival benefit in multiple preclinical glioma models. Mechanistically, loss of Chek2 enhances antigen presentation, STING pathway activation and PD-L1 expression in mouse gliomas. Analysis of human GBMs demonstrates that Chek2 expression is inversely associated with antigen presentation and T-cell activation. Collectively, these results support Chek2 as a promising target for enhancement of response to immune checkpoint blockade therapy in GBM.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (1R01NS110703)
- CU | National Cancer Institute, Cairo University (R01 CA120813, P50CA221747)
- U.S. Department of War (W81XWH-20-1-0850)
This publication has 67 references indexed in Scilit:
- Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cellsJournal of Experimental Medicine, 2011
- Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumorsNeuro-Oncology, 2011
- Molecular signatures database (MSigDB) 3.0Bioinformatics, 2011
- Intratumoral Mediated Immunosuppression is Prognostic in Genetically Engineered Murine Models of Glioma and Correlates to Immunotherapeutic ResponsesClinical Cancer Research, 2010
- Glioma cancer stem cells induce immunosuppressive macrophages/microgliaNeuro-Oncology, 2010
- Glioblastoma Cancer-Initiating Cells Inhibit T-Cell Proliferation and Effector Responses by the Signal Transducers and Activators of Transcription 3 PathwayMolecular Cancer Therapeutics, 2010
- Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like propertiesNeuro-Oncology, 2009
- Incidence and Prognostic Impact of FoxP3+ Regulatory T Cells in Human GliomasClinical Cancer Research, 2008
- Glioma stem cells promote radioresistance by preferential activation of the DNA damage responseNature, 2006
- The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses1Neuro-Oncology, 2006